Results of a multicenter randomized study on the efficacy and toxicity of therapy in patients with Hodgkin’s lymphoma of intermediate-risk group

Summary. This article presents the analysis of the immediate results of complex treatment of 111 Hodgkin’s lymphoma patients from intermediate prognostic group (stage IIA and IIB with the presence of one or more unfavorable factors), who were treated at the National Cancer Institute (Kyiv) and the Crimean Republican Institution «Clinical Oncological Dispensary named after V.M. Efetov» (Simferopol) from 2009 to 2014 (study group). Efficiency of treatment of the patients with intermediate-risk Hodgkin’s lymphoma with 2 cycles of BEACOPP-esc + 4 cycles of ABVD is similiar with 6 cycles of BEACOPP-esc, but has a much lower toxicity profile.